Record $3.5B in Awards Meets a Sequential EBITDA Decline and a Year That Now Rides Entirely on Q4 — The Demand Is Unquestionable, the Profitability Path Is Not

Results vs. Consensus

Year-Over-Year and Sequential Comparison

Quality of the Quarter

Revenue: The top line is the unambiguous positive. The +9% pro-forma growth would have been higher absent the shutdown, and legacy organic +21% shows the core franchise is accelerating, not fading. Within AxS (+15.7% pro-forma), Precision Strike & Counter-UAS led with ~38% growth on Switchblade 600 and Titan; uncrewed systems grew 8% (and >50% ex-Ukraine on Jump 20 strength). SCDE (~flat) was the casualty of the shutdown — space and directed energy grew >20% but cyber emission systems declined on discontinued programs and shutdown disruption.

Margins: The quarter's problem, and the reason for the downgrade. Adjusted gross margin of 27% (from 41% YoY, 29% sequentially) absorbed: (1) one-time Oracle Fusion ERP go-live inefficiencies and costs; (2) the government shutdown, which delayed higher-margin FMS shipments and cost SCDE revenue; and (3) unfavorable service/product mix. Adjusted EBITDA margin of 9.5% is the lowest of the combined era. Management insists adjusted gross margin recovers to the high-30s by Q4 (low-30s for the year) and EBITDA to 15–16% full-year — but that recovery is now entirely a Q4 event.

EPS: Two distinct things, often conflated. (1) The $0.44 print missed the ~$0.79–0.87 Street consensus by ~45% — a genuine expectations miss driven by the margin shortfall — yet was only modestly below the $0.47 prior-year Q2. (2) The FY26 EPS guide cut to $3.40–3.55 (from $3.60–3.70) is tax-driven: a higher full-year projected tax rate from the Q2 update of the BlueHalo purchase-price allocation, not an operating reduction. Revenue and EBITDA guidance held; the revenue floor was raised. GAAP remains a ~$67M net loss on amortization and integration cost — management continues to guide non-GAAP only.

Segment Performance

The split personality from Q1 persisted: AxS grew and carried the profitability; SCDE was flat and bore the brunt of the shutdown. The combined gross-margin pressure is concentrated in the early-stage, service-heavy parts of the portfolio.

Autonomous Systems (AxS) — $302M, +15.7%, Still the Engine

AxS grew 15.7% pro-forma with Precision Strike & Counter-UAS up ~38% (Switchblade 600 and Titan), and uncrewed systems up >8% (>50% ex-Ukraine on Jump 20). The program wins were marquee: the ~$1B P550 LRR down-select, the Jump 20 selection as one of four options on the U.S. Navy's basic ordering agreement, the ~$874–900M international small-UAS/Titan IDIQ, and the HMIF software-integration award that makes AV the lead software/system integrator for tactical-edge robotics.

Assessment: AxS remains the franchise and continues to do exactly what it should — grow mid-teens, win programs, throw off the bulk of the profit. The downgrade is not an AxS story; AxS is the reason the rating is Hold rather than something lower. The HMIF software win is strategically important and under-appreciated: it embeds AV's command-and-control layer across the Army's robotic edge.

Space, Cyber & Directed Energy (SCDE) — $171M, ~flat, Still the Question Mark

SCDE was roughly flat pro-forma, the segment hardest hit by the shutdown (lost revenue plus revenue-recognition delays). Underneath, space and directed energy grew >20% (LOCUST a key driver), while cyber emission systems declined on discontinued programs. The award flow was enormous — the $240M (up to ~$380M with options) laser-comm contract, two more BADGER phased-array systems under SCAR, and the $499M Helmssman electromagnetic-protection program — but little of it converted to Q2 revenue or margin.

Assessment: SCDE is exactly where the thesis is being tested, and Q2 did not advance the case. The segment is still near-breakeven, and the margin inflection management has promised since the deal closed keeps getting pushed out — now pinned on SCAR/BADGER transitioning from customer-funded development to firm-fixed-price product in H2. The programs are real and large; the profitability remains unproven a second consecutive quarter. This is the crux of the downgrade.

Key Topics & Management Commentary

Overall Management Tone: Confident on demand, insistent on the back-half recovery, and noticeably more defensive on margins and timing than in Q1. Management led with the record $3.5B award ceiling and the program wins, framed the margin and EBITDA softness as shutdown- and ERP-driven and transient, and leaned hard on the "70% of H2 EBITDA in Q4" math as the path to the maintained full-year guide. The posture asks investors to look past two soft profitability quarters to a Q4 inflection — a bigger ask than at any point since the deal closed.

1. Record Awards vs. a Sequential EBITDA Decline

"The total ceiling value of new contract awards during Q2 reached $3.5 billion, a historic record achievement by AV. This also resulted in record second quarter bookings of nearly $1.4 billion." — Wahid Nawabi, Chairman, President & CEO

The demand side could hardly have been stronger: a $3.5B award ceiling, $1.4B of bookings, 2.9x book-to-bill, and legacy organic +21%. Yet adjusted EBITDA fell to $45.0M (9.5%) from $56.6M (12.4%) sequentially.

Assessment: This is the central tension of the print and the quarter in one line: the best order book in company history alongside the worst-trending profitability of the combined era. For a stock priced on a back-half margin ramp, sequential EBITDA contraction is the data point that matters — it raises the bar for an already-steep Q4 and is the proximate trigger for moving to the sidelines.

2. The Q4 Cliff: 70% of Second-Half EBITDA in One Quarter

"Second half revenue should be split approximately 45% in Q3 and 55% in Q4. The adjusted EBITDA shift will be more pronounced, with 70% of the second-half EBITDA coming in the fourth quarter." — Kevin McDonnell, EVP & CFO

To hit the maintained $300–320M full-year EBITDA after a $56.6M + $45.0M first half (~$102M), the back half must deliver ~$200–220M, with ~70% — roughly $140–150M — in Q4 alone. Adjusted gross margin must simultaneously jump from 27% to the high-30s in that quarter.

Assessment: This is the single most important — and most precarious — disclosure in the print. A year that concentrates 70% of its second-half profit in the final quarter has almost no margin for error; any slippage in funding timing, FMS shipments, or the SCAR/BADGER production transition compresses directly into a Q4 miss. The demand supports the revenue; the EBITDA concentration is an execution tightrope, and it is the analytical heart of the downgrade.

3. The EPS Guide Cut Is Tax-Driven, Not Operational

"Non-GAAP adjusted EPS is now projected to be between $3.40 and $3.55. The lower non-GAAP EPS range is a result of a higher full-year projected tax rate, largely driven by the Q2 update of the purchase price allocation of the BlueHalo acquisition." — Kevin McDonnell, CFO

Crucially, revenue guidance was raised at the low end (to $1.95–2.0B) and adjusted EBITDA was maintained ($300–320M). The EPS reduction is a tax-rate artifact of finalizing the BlueHalo purchase-price allocation, not a cut to operating expectations.

Assessment: An important nuance the headline "guidance cut" obscures. Operationally, the guide firmed (higher revenue floor, same EBITDA). The EPS line came down for a non-operating reason. This tempers the bear read — but it does not rescue the rating, because the issue isn't the guide number, it's the EBITDA cadence and margin trajectory behind it.

4. Gross Margin at 27%: ERP, Shutdown, and Mix

"We went live with our Oracle Fusion ERP system upgrade in the quarter… we experienced some operational inefficiencies and one-time costs… we also saw an unfavorable service product mix… partially as a result of the government shutdown caused by delays in FMS shipments… we believe the adjusted gross margin should improve in Q3 and be in the high 30s by Q4." — Kevin McDonnell, CFO

The 27% adjusted gross margin (vs. 41% YoY) reflects three identifiable drags — the ERP go-live, the shutdown's FMS/SCDE hit, and mix. Management reaffirmed the low-30s full-year, high-30s Q4 path, driven by product revenue (BADGER/SCAR, LOCUST) growing faster than service revenue in H2.

Assessment: The causes are credible and largely transient, and the product-over-service mix shift is a real margin lever. But "high-30s by Q4" is now a one-quarter, ~1,000bp move off 27% — a steep, unproven step. After two quarters of margin disappointment, the burden of proof is squarely on management, and we won't pay an Outperform multiple to find out.

5. The Government Shutdown Pushed Funding — and Revenue — to the Right

"Because of the continuing resolution… those dollars have not made it into the accounts of our customers to be able to then award task orders against those IDIQs. So we expect a significant number of additional funded task orders in Q3 and Q4." — Wahid Nawabi, CEO

The ~6-week shutdown both disrupted Q2 deliveries and, more importantly, delayed the flow of Big Beautiful Bill / DoW appropriations into customer accounts — so the task orders against AV's $3.5B of (largely sole-source IDIQ) awards are still pending. Funded backlog was roughly flat at $1.1B despite the record award ceiling, precisely because funding hadn't been released.

Assessment: This explains the flat funded backlog and is genuinely exogenous — not a demand problem. But it adds timing risk on top of the margin-ramp risk: the H2 revenue that feeds the Q4 EBITDA cliff depends on appropriations reaching accounts and converting to task orders "in the next 1–2 months." Two stacked timing dependencies into a single make-or-break quarter is more risk than the multiple compensates for.

6. The Program Wins: P550 LRR, HMIF, Laser Comm, Helmssman, $874–900M IDIQ

"Our P550 was recently down-selected by the U.S. Army's Long Range Reconnaissance Program… estimated to be worth approximately $1 billion… we were recently awarded an $874 million sole-sourced IDIQ contract from the U.S. Army for international sales… AV was awarded a contract valued at $499 million by the U.S. Air Force Research Laboratory… known as Helmssman." — Wahid Nawabi, CEO

The award slate was extraordinary across both segments: the ~$1B P550 LRR down-select, the HMIF software-integration win (AV as lead robotics software integrator), the ~$874–900M international small-UAS/Titan IDIQ, the $499M Helmssman directed-energy-protection program, the $240M (up to ~$380M) laser-comm contract, and additional BADGER/SCAR options.

Assessment: The pipeline is converting into awards at a remarkable clip — this is why the downgrade is to Hold, not lower. These wins underwrite multi-year growth and validate the platform strategy. The gap is purely between awards and funded/recognized revenue-and-margin, which the shutdown widened. The demand thesis is intact; the timing and profitability are the issue.

7. AV HALO Software: The HMIF Win and Platform Momentum

"As part of this win, AV is going to be the lead software and system integrator for robotic systems on the edge of the battlefield. This award… underscores the Army's confidence in AV's ability to deliver mission-critical solutions." — Wahid Nawabi, CEO

AV HALO added modules (Cortex intelligence-fusion, Mentor training) and an OpenJAUS collaboration for cross-OEM interoperability, on top of the HMIF program win. Management positioned HALO's hardware-agnostic, competitor-interoperable architecture as an increasingly decisive factor in DoD procurement.

Assessment: The software layer continues to build strategic weight, and the HMIF win is a genuine validation — being the C2 software integrator for the Army's robotic edge is a durable, potentially higher-margin position. It is the most encouraging forward development in the quarter and a key reason the franchise still merits a constructive long-term view even as we step to the sidelines.

8. Switchblade Capacity Doubling to $2B+ (Salt Lake City)

"This new factory has the potential capacity to produce over $2 billion worth of Switchblades or other AV products per year. We anticipate this factory to be operational about a year from now." — Wahid Nawabi, CEO

The new ~100,000-sq-ft Salt Lake City facility roughly doubles the prior ~$1B Switchblade capacity framing to $2B+ (multi-shift), and is deliberately flexible — able to produce Switchblade variants, Red Dragon one-way attack, non-lethal UAS, or FE1. Manufacturing now spans 12 states.

Assessment: The capacity build is demand-pulled and sensible, and the doubling versus prior framing signals management's confidence in sustained loitering-munition/one-way-attack demand. It is a FY27+ growth enabler, not a FY26 factor — and it adds to the CapEx that pressures near-term free cash flow.

9. Working Capital, Unbilled Receivables, and the 50% Cash-Conversion Goal

"We've always tried to say that we can get our EBITDA cash conversion over 50%… that's EBITDA less our CapEx, less our working-capital change." — Kevin McDonnell, CFO

Cash fell to $669M (from $722M), and unbilled receivables remained elevated as over-time revenue recognition rose to 75% (from 41%) and Precision Strike revenue grew 68% H1. Management expects unbilled to come down materially in H2 and targets ~50% EBITDA-to-cash conversion for the year (EBITDA less CapEx less working-capital change), with CapEx "a little less than half" of EBITDA.

Assessment: The cash story is improving in intent but unproven in fact — another "it happens in H2" commitment. Management is explicitly taking "calculated risk" by building product ahead of task orders to capture H2 demand, which front-loads working capital. The 50% conversion target is achievable only if Q4 lands as planned; it is one more line item levered to the same back-half bet.

Guidance & Outlook

The guidance shape tells the whole story: revenue floor up, EBITDA held, EPS down on tax, visibility up to 93% — but profitability concentrated into Q4 to a degree that leaves little room for error. The maintained EBITDA after a soft first half is, mathematically, a promise that Q4 will be exceptional. Management's confidence rests on the $3.5B of sole-source IDIQ awards converting to funded task orders "in the next 1–2 months" as appropriations flow post-shutdown.

Implied Q4: First-half EBITDA of ~$102M against a $310M midpoint implies ~$208M in H2, with ~70% (~$145M) in Q4 — versus $45M in Q2. That is a ~3x sequential EBITDA step and a gross-margin jump from 27% to the high-30s, in one quarter. Revenue cadence is ~45% Q3 / 55% Q4.

Street at: The ~45% EPS miss and the EBITDA-cadence disclosure will push the Street to de-risk Q4 estimates and scrutinize the margin-recovery assumption. Consensus EPS resets toward the $3.40–3.55 guide; the debate shifts entirely to whether the Q4 EBITDA cliff is achievable.

Guidance style: Confident-but-stretched. Raising the revenue floor and holding EBITDA after a sub-10% EBITDA-margin quarter is an assertive stance that bets heavily on Q4. Management was candid that funding timing is the swing variable and explicitly declined to raise further because "exactly when [task orders] are going to come in is anybody's guess" — an honest hedge that also underscores the risk.

Analyst Q&A Highlights

The Q4 Profitability Ramp: Operating Leverage vs. Mix

The opening line of questioning pressed directly on the credibility of the back-half margin ramp given the Oracle and shutdown headwinds, and what actually drives the high-30s Q4 gross-margin target. Management attributed it primarily to mix — product revenue (BADGER/SCAR, LOCUST) outgrowing service revenue — rather than pure operating leverage.

Q: "If you think about that ramp of profitability and margin given the 70% in Q4, how are you thinking about that progression? How much is operating leverage versus maybe mix and just the biggest drivers?"
— Greg Konrad, Jefferies

A: "Mix is going to be a big part of that… the BADGER program going into fixed-price product revenues, [and] LOCUST and things like this being product revenues… increasing the proportion of product revenues versus service revenues… that's why we're going to be able to achieve the high 30s adjusted gross margins by the fourth quarter."
— Kevin McDonnell, CFO

Assessment: The mix-shift mechanism is real and identifiable, which is reassuring — but it is also entirely a Q4 event, dependent on SCAR/BADGER and LOCUST transitioning to product revenue on schedule. The answer explains how the ramp could work; it does not de-risk the concentration. After two soft margin quarters, "it happens in Q4" is exactly the bet we're unwilling to underwrite at a full multiple.

Flat Backlog Despite a Record $3.5B in Awards

A pointed exchange probed why funded backlog was roughly flat sequentially despite the record award ceiling, and whether backlog ramps into the back half. Management tied the flatness directly to the shutdown and continuing resolution delaying the funding behind the awards.

Q: "If I'm looking at the backlog in 1Q versus 2Q, it's slightly down… Should we see the backlog significantly ramping into the back half of the year? Or is it just so unpredictable?"
— Anthony Valentini, Goldman Sachs

A: "It's pretty flat from Q1 in terms of the funded backlog… we were in the CR and the shutdown. So while we got many of these contracts through… a lot of them didn't come with significant funding, and we expect that to be coming as they get back to… funding new contracts within the Department of War."
— Kevin McDonnell, CFO

Assessment: A credible, exogenous explanation — the awards are real, the funding is delayed. But it crystallizes the core risk: the demand has been won, yet its conversion to funded backlog (and thence to H2 revenue and the Q4 EBITDA cliff) waits on appropriations flowing through a post-shutdown bureaucracy. The award ceiling is reassuring for FY27; the FY26 timing is not de-risked.

When Does SCDE Reach EBITDA Breakeven?

One exchange pressed specifically on SCDE's margin profile and when the segment's adjusted EBITDA turns clearly positive. Management framed the shutdown as the dominant near-term drag and reiterated conviction in the segment's long-run profitability as it shifts toward product revenue.

Q: "Could you discuss the margin profile of the SCD&E segment? Is there maybe a time when you think that the adjusted EBITDA will be breakeven?"
— Pete Schaffrik (for Ken Herbert), RBC Capital Markets

A: "It will continue to grow throughout the year… they were probably the most impacted by the government shutdown of any of our businesses… their product mix is going to increase over their service mix. So that is going to drive their EBITDA margins up."
— Kevin McDonnell, CFO; Wahid Nawabi, CEO

Assessment: Management would not commit to a breakeven timeline — the second consecutive quarter the SCDE margin inflection has been asserted but not dated. The conviction may well be warranted (the programs are real and product-bound), but a near-breakeven, ~$170M segment whose profitability is perpetually "next quarter" is precisely the unproven piece that caps the rating at Hold.

The Laser-Comm Contract Size and Funding Status

An exchange sought to reconcile the laser-comm contract figures (a $240M number versus a larger $380M+ in the slides) and whether terminals were shipping or the award was funded. Management clarified the base-versus-options split and was candid that the bulk is not yet funded.

Q: "Was that contract recently upsized from $240 million to $385 million?… And have you started delivering terminals as part of that program?… As part of the original committed contract, is it funded already?"
— Louie DiPalma, William Blair

A: "The $381 million includes the options… the $240 million was the original committed contract… [and] the vast majority of that contract is not funded yet… because of the continuing resolution… those dollars have not made it into the accounts of our customers."
— Kevin McDonnell, CFO; Wahid Nawabi, CEO

Assessment: The flagship SCDE program crystallizes the whole quarter: a landmark, technology-leading award where AV beat major primes — but mostly unfunded, barely delivering, and not yet contributing margin. It is the future earnings power the depressed current margins are paying for, and a microcosm of the awards-vs-funded-revenue gap that defines FY26.

Unbilled Receivables and the 50% Cash-Conversion Target

A recurring line of questioning pressed on why unbilled receivables kept rising despite a new contractor-payment schedule, and whether free cash flow can reach the targeted conversion. Management pointed to the over-time revenue-recognition shift and a deliberate decision to build product ahead of task orders.

Q: "Your Precision Strike product revenues were up 68% for the first six months… but unbilled continues to grow… Could you give us a little more color on what's going on there?"
— Multiple analysts incl. Peter Arment, Baird; Colin Canfield, Cantor Fitzgerald

A: "We have a clear runway to continue to start bringing that down [in] the second half… [CEO:] we're really more focused on top-line growth… we're anticipating a lot more task orders in the second half… so we have to really start building products in advance… taking some calculated risk to position ourselves to deliver."
— Kevin McDonnell, CFO; Wahid Nawabi, CEO

Assessment: Candid and revealing. Management is deliberately front-loading working capital — building inventory ahead of funded orders — to avoid losing the demand it sees coming. That is the right strategic instinct, but it deepens the cash and working-capital draw now in exchange for an H2 conversion that, like the margin ramp, is promised rather than proven. The 50% conversion target hinges on Q4.

P550 LRR: Sole-Source or Continued Competition?

A clarifying exchange sought to pin down AV's status on the ~$1B P550 Long Range Reconnaissance program after multiple awards. Management explained the Army's evolving multi-vendor procurement model and AV's expected share.

Q: "Are you guys sole-sourced now on LRR with the P550? Or is there going to be an ongoing competition over the next few years?"
— Pete Skibitski, Alembic Global

A: "More the latter… the traditional construct of a program of record single winner probably is not going to be that popular… they're going to pick at least 2 players… as the performance of that system is better, that vendor most likely is going to get the lion's share… We expect to get a large share."
— Wahid Nawabi, CEO

Assessment: A realistic answer that reflects the DoD's broader shift to multi-vendor, performance-based awards (echoing the scalability-hedging theme from Q1). AV's claimed performance edge and capacity advantage make "lion's share" plausible, but LRR is a competitive share game, not a locked sole-source — appropriate to model as probability-weighted rather than guaranteed.

What They're NOT Saying

1. A dated SCDE breakeven/margin path: Two quarters in, management still won't put a timeline on when SCDE's EBITDA margin meaningfully inflects — only "it improves in H2." The biggest unanswered question in the story.
2. The bridge to a ~$145M Q4 EBITDA: The 70%-in-Q4 framing was given, but no granular build (program-by-program) for how EBITDA roughly triples sequentially. Investors must take the ramp on faith.
3. Quantified ERP go-live cost: The Oracle Fusion go-live was cited as a one-time gross-margin drag but never sized — leaving the "underlying" Q2 margin un-bracketed.
4. FY27 framing: Management repeatedly teased that the funding/awards set up FY27 well but explicitly declined to provide any FY27 guidance or growth range — understandable, but it leaves the multi-year algorithm undefined just as the FY26 ramp gets riskier.
5. Hard free-cash-flow guidance: Still only a "~50% EBITDA conversion" goal, not a dollar figure, despite a rising unbilled balance and a deliberate build-ahead-of-orders strategy.

Market Reaction

• Pre-print setup: Shares entered the print around ~$284, near all-time highs, having roughly doubled off the ~$116 FY25 Q3 low and risen ~50% from the ~$190 level at the September Q1 print on relentless defense-tech/drone enthusiasm. The stock was priced for flawless execution.
• After-hours / day-of move: Down ~10%+, falling from ~$284 toward ~$251 and erasing roughly $1.6B of market value, despite record bookings and a revenue beat. The market sold the sequential EBITDA decline, the 27% gross margin, the ~45% EPS miss versus consensus, and the all-on-Q4 cadence.

The sell-off is the clearest evidence for the downgrade thesis: when a stock priced for perfection delivers record demand but deteriorating profitability and a year that hinges on one quarter, the order book doesn't save it. The market looked past the $3.5B award ceiling and focused on the same things we do — EBITDA going the wrong way, margins still depressed, and a Q4 that has to be near-flawless. The ~10% drawdown rationally re-rates a name that had run too far ahead of its margin reality.

Street Perspective

Debate: Is the Q4 EBITDA Ramp Achievable?

Bull view: The drags are identifiable and transient (ERP go-live, shutdown), the mix shift to product revenue (SCAR/BADGER, LOCUST) is real, and the $3.5B of sole-source IDIQ awards convert to task orders as appropriations flow — the high-30s Q4 gross margin and ~$145M Q4 EBITDA follow mechanically.

Bear view: Tripling EBITDA sequentially and adding ~1,000bp of gross margin in a single quarter — after two quarters of margin misses — is a heroic assumption stacked on funding-timing risk the company itself can't control. The "it all happens in Q4" story rarely survives contact with a post-shutdown appropriations cycle.

Our take: Achievable but far from assured, and the asymmetry is unattractive: deliver and the stock holds; slip and a perfection-priced name de-rates again. That risk/reward is the definition of a Hold. We need to see the ramp begin in Q3, not just be promised for Q4.

Debate: Demand Is Unquestionable — Does That Make the Stock a Buy?

Bull view: A $3.5B award ceiling, 2.9x book-to-bill, legacy +21% organic, and a 20-program/$20B-plus pipeline make AV the best-positioned mid-cap in defense; the margin softness is timing noise around a secular demand explosion.

Bear view: Demand was never the question; profitability and cash conversion are. Awards that aren't funded, revenue that isn't recognized, and EBITDA that's declining don't pay for a ~70x forward-EPS multiple.

Our take: Both can be true — and they are. The demand underwrites the long-term franchise and floors the rating at Hold; the unproven profitability and full valuation cap it there. Great company, demanding price, deferred proof.

Debate: Is the EPS Guide Cut a Warning or a Footnote?

Bull view: It's a footnote — a tax-rate artifact of finalizing the BlueHalo purchase-price allocation. Revenue floor was raised, EBITDA held; the operating story didn't weaken.

Bear view: Whatever the cause, the EPS number came down a quarter after a "27% raise," reinforcing a perception of guidance volatility and an EPS line whipsawed by below-the-line items the company can't steer.

Our take: Mechanically the bulls are right — this is tax, not operations. But the optics matter for a stock that just ran on the Q1 raise: a raise-then-trim within two quarters, even for non-operating reasons, erodes the "clean compounding" narrative. We treat it as a footnote to the rating but a real dent to sentiment.

Model Update

Valuation: At ~$251 post-drop (down from ~$284) on ~47M shares, market cap is ~$11.8B and EV ~$12B. That is ~37–38x FY26E adjusted EBITDA midpoint ($310M), ~6x EV/sales, and ~70x the midpoint FY26E EPS of ~$3.48 — a premium-to-peers multiple that prices sustained high-teens growth and a successful margin inflection. Even at ~$284 pre-print, the multiple left no room for the EBITDA wobble the quarter delivered. Fair-value framing: the demand and pipeline justify a growth premium, but not a flawless-execution premium into a quarter that just showed sequential EBITDA contraction. We see balanced-to-unfavorable risk/reward at ~$251 and would want either a Q3 that visibly begins the margin ramp or a more meaningful pullback before paying up again.

Thesis Scorecard Post-Earnings

Overall: Thesis weakened on the dimensions that now matter. The demand and pipeline are stronger than ever, but the profitability trajectory deteriorated (sequential EBITDA decline, sticky 27% gross margin), the recovery is concentrated into a single high-stakes Q4, and the valuation offers no cushion. The balance has tipped from favorable to merely fair.

Action: Downgrading to Hold from Outperform. This is not a call against the franchise — AV has the best demand profile in mid-cap defense and a remarkable award slate. It is a call on risk/reward: we will not pay a perfection multiple while EBITDA is moving backward and the entire year depends on a Q4 that must roughly triple sequential profit and add ~1,000bp of gross margin amid funding-timing risk. We would move back to Outperform on (1) a Q3 that visibly begins the margin/EBITDA ramp, (2) clear evidence SCDE's profitability is inflecting, or (3) a pullback that restores a margin of safety. We would move to Underperform if the Q4 ramp slips and the margin story fails to materialize.